Producer

Merck KGaA (MilliporeSigma in US)

MRKHQ DEwebsite ↗

German multinational producing the Hi-Flow Plus nitrocellulose membrane — one of the two industry-standard LFA membranes globally. Received a €121M US DoD/HHS contract to build the first US lateral flow membrane facility in Sheboygan, WI (2022) to reduce concentration risk in Cork, Ireland.

6

Inputs supplied

2

Goods downstream

3

Facilities

0

Stories

Where it shows up

Goods downstream

Essential goods that depend on something Merck KGaA (MilliporeSigma in US) makes — pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map — where this supply-chain role fits within their broader business.

  • Life Science (MilliporeSigma — US Brand)

    42%
  • Healthcare (Pharma — Small Relative to Life Science)

    22%
  • Electronics / Performance Materials (Liquid Crystals & OLED)

    28%
  • Surface Solutions & Specialty Chemicals

    8%

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

  • Did you know2023

    Merck KGaA (Darmstadt, Germany) — known in the US as MilliporeSigma (lab chemicals and COVID test membranes) and as a pharmaceutical company — controls approximately 70% of global liquid crystal supply for LCD flat-panel displays. Every LCD television, laptop screen, desktop monitor, and industrial display uses liquid crystal molecules to control light transmission; Merck KGaA's Liquid Crystals division (part of Electronics/Performance Materials) supplies those molecules to LCD panel manufacturers in Korea (Samsung, LG), Japan (Sharp, Japan Display), and China (BOE, CSOT). A 1668-founded German pharmacy is the invisible supplier of display technology in virtually every flat-panel screen sold globally. Merck's liquid crystal dominance is a natural monopoly derived from 50+ years of proprietary mixture formulation expertise — each new display generation requires new custom LC mixtures developed by Merck's chemists.

    Merck KGaA
  • Capacity2021

    In 2022, the US Department of Defense and HHS awarded Merck KGaA (MilliporeSigma) a €121M contract to build the first US domestic lateral flow assay membrane manufacturing facility in Sheboygan, Wisconsin. The contract was motivated by COVID-19 supply chain analysis: virtually all nitrocellulose membrane for US rapid tests was produced at Merck's Carrigtwohill, County Cork, Ireland facility — a single European site producing critical US public health infrastructure. A production disruption at Cork would have crippled US COVID, flu, and RSV testing capacity. The Sheboygan facility is designed to produce Merck's Hi-Flow Plus NC membrane for the US government strategic stockpile and commercial test manufacturers — the first new US membrane manufacturing investment in decades, prompted entirely by supply chain vulnerability recognition from the COVID pandemic.

    MilliporeSigma (Merck KGaA)